Drug intelligence / Profile preview

CT104

Development stage: Preclinical
Lead developer: Cura Therapeutics
Modality: Recombinant Proteins and Enzymes

Overview

CT104 is an engineered recombinant protein being developed by Cura Therapeutics as a longevity immunotherapy. It is designed to target aging-related conditions by focusing on anti-senescence mechanisms. As part of Cura's platform of engineered proteins, CT104 aims to modulate the immune system to address cellular senescence, although its specific molecular target and detailed mechanism of action have not been publicly disclosed. The program is currently in the preclinical stage of development, with the next anticipated milestone being the achievement of preclinical proof-of-concept.

Targets

CD4 (T lymphocyte surface antigen)TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on CT104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT104.

Explore the full profile